GLP-1受体激动剂降低糖尿病合并CKD患者痴呆与阿尔茨海默病风险
本研究基于TriNetX全球研究网络回顾性队列,纳入2015至2020年间新处方GLP-1RA或DPP4i的CKD 3期及以上合并T2DM患者。
要点
- CKD 3期及以上合并T2DM患者使用GLP-1RA与痴呆风险降低20%相关
- 血管性痴呆、额颞叶痴呆、帕金森病等未见显著差异
核心结论
- GLP-1RA治疗可能降低CKD 3期及以上合并T2DM患者的痴呆和阿尔茨海默病风险,提供降糖之外的潜在神经保护获益。
研究设计与样本
- 回顾性队列研究,数据来自TriNetX全球研究网络美国协作网络67家医疗机构的电子病历。
- 纳入2015年1月1日至2020年12月31日新处方GLP-1RA或DPP4i的CKD 3期及以上合并T2DM患者。
- 排除既往使用GLP-1RA或DPP4i、索引日期前12个月内诊断痴呆或近期住院的患者。
- 随访90天至5年,采用Kaplan-Meier生存曲线和Cox比例风险模型分析。
主要发现
- 血管性痴呆、额颞叶痴呆、帕金森病、锥体外系和运动障碍、路易体痴呆未见显著差异。
临床怎么用
- 对于CKD 3期及以上合并T2DM患者,选择GLP-1RA而非DPP4i可能同时带来降糖和降低痴呆风险的获益。
局限性
- 研究为回顾性队列设计,可能存在残余混杂。
- 结论需进一步研究确认并优化该脆弱人群的治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) are at increased risk of developing dementia and Alzheimer's disease due to vascular dysfunction, insulin resistance and chronic inflammation. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown neuroprotective properties; however, their impact on dementia risk in diabetic patients with CKD remains uncertain. This study evaluated the association between GLP-1RA use and dementia risk in patients with CKD stage 3 or later, compared with dipeptidyl peptidase-4 inhibitors (DPP4is). METHODS: This retrospective cohort study analyzed data from the TriNetX global research network, comprising electronic medical records from 67 healthcare organizations in the US Collaborative Network. We identified patients with CKD stage 3 or later and T2DM who were newly prescribed GLP-1RAs or DPP4is between 1 January 2015 and 31 December 2020. Patients with prior GLP-1RAs or DPP4i use, a dementia diagnosis within 12 months before the index date or recent hospitalization were excluded. The primary outcome was the incidence of dementia, Alzheimer's disease, vascular dementia, frontotemporal dementia, Parkinson's disease, extrapyramidal and movement disorders, and dementia with Lewy bodies, assessed over a follow-up period ranging from 90 days to 5 years. Statistical analyses included Kaplan-Meier survival curves and Cox proportional hazards models. RESULTS: GLP-1RA use was associated with a significantly lower risk of dementia [hazard ratio (HR) 0.80, 95% confidence interval (CI) 0.71-0.91, P = .001] and Alzheimer's disease (HR 0.76, 95% CI 0.59-0.98, P = .033) compared with DPP4i use. However, no significant differences were observed in vascular dementia, frontotemporal dementia, Parkinson's disease, extrapyramidal and movement disorders, or dementia with Lewy bodies. CONCLUSIONS: GLP-1RA therapy may reduce the risk of dementia and Alzheimer's disease in patients with CKD stage 3 or later, offering potential neuroprotective benefits beyond glycemic control. Research is needed to confirm these findings and optimize treatment strategies for this vulnerable population.
引用
- Lee WT, Wang JT, Tsai MH, et al. GLP-1 receptor agonists reduce dementia and Alzheimer disease risk in diabetic patients with CKD. Nephrol Dial Transplant. 2026. PMID: 41697144. doi:10.1093/ndt/gfag032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。